diaTribe’s Community Manager Cherise Shockley led an online discussion about Time in Range with Shay Webb, a diabetes advocate, and Julia Blanchette, a diabetes care and...
Time in Range News
Time in Range (TIR) is the percentage of time that a person spends with their blood glucose levels in the target range, usually between 70 and 180 mg/dl.
39 readers recommended
The Association of Diabetes Care and Education Specialists 2021 conference covered the impacts of diabetes stigma, smart MDI therapies, insulin delivery by means other...
36 readers recommended
Coming to US in Spring 2017: What it is, what it isn’t, and how to get it
16 readers recommended
How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?
19 readers recommended
Tripling my carbs --> 5 fewer hours in-range per day, 64% more insulin (!), & more lessons learned.
52 readers recommended
The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?
23 readers recommended
Strong results from the IMPACT study in low-A1c users.
53 readers recommended
Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!
50 readers recommended
What does A1c miss and what can we do about it?
22 readers recommended
The diaTribe Foundation convenes key diabetes experts to discuss glycemic outcomes beyond A1C on July 21, 2017, in Bethesda, MD
17 readers recommended
What does donated diabetes data tell us about time-in-range across different age groups?
37 readers recommended
Get weekly email and phone notifications summarizing time-in-range and glucose trends from the updated Dexcom Clarity app
55 readers recommended
Farxiga and Sotagliflozin are the first pills to seek approval as add-ons to insulin for type 1; both bring strong time-in-range benefits, and if approved, might launch...
21 readers recommended
The world’s first all-diabetes professional cycling team is now sponsored by Dexcom; diabetes research studies on CGM and exercise will start this year: What is the...
17 readers recommended
Using time-in-range to assess risk for complications, Omnipod Horizon Closed Loop, Bihormonal closed loop (insulin + Pramlintide), SGLT-2 oral drug for type 1, and more!
22 readers recommended
From clinical expertise and personal experience as a type 1, Dr. Sherr shares valuable (and exciting) perspectives on diabetes treatments.
22 readers recommended
Read about a new cauliflower pizza crust, alongside updates on Senseonics Eversense CGM, Medtronic’s new CGM points program, the Beyond A1C movement, Tandem’s Basal-IQ,...
22 readers recommended
Updates to the Clarity app allow G5 and G6 CGM users to set a daily time-in-range goal and be notified when it is reached, awesome Bright Spots pattern recognition in...
20 readers recommended
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
26 readers recommended
The latest updates on time-in-range goals for people with all types of diabetes, and insights linking FreeStyle Libre scanning frequency to outcomes.